MOGAD in Children with Suspected MS

Prior research identified markers that differentiated adult patients with multiple sclerosis (MS) from those who have neuromyelitis optica spectrum disorder (NMOSD), with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) or aquaporin-4–positive (AQP4+) disease (NEJM JW Neurol Dec 13 2022 and Neurology 2022 Oct 3; [e-pub]).

Now, to determine the frequency of MOGAD and AQP4+ disease in pediatric patients with suspected MS, investigators conducted a prospective multicenter, cross-sectional, seroprevalence, case-control study involving 493 patients with a working diagnosis of pediatric-onset MS (POMS; mean age, 15.4 years) and 703 healthy controls (mean age, 14.7 years). Serum MOG-IgG and AQP4-IgG were assessed in study par…